Focused On-demand Library for Proteasome activator complex subunit 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q14997

UPID:

PSME4_HUMAN

Alternative names:

Proteasome activator PA200

Alternative UPACC:

Q14997; Q1XBG4; Q1XBG5; Q1XBG6; Q2M1Z0; Q6IPR2; Q86XF8

Background:

Proteasome activator complex subunit 4, also known as Proteasome activator PA200, plays a crucial role in cellular processes such as spermatogenesis and DNA damage response. It uniquely recognizes acetylated histones, promoting their ATP- and ubiquitin-independent degradation. This protein binds acetylated histones via its bromodomain-like region and activates the proteasome, facilitating substrate entry without the need for ATP or ubiquitin. Its involvement in the spermatoproteasome, a testis-specific proteasome form, underscores its importance in histone exchange during spermatogenesis.

Therapeutic significance:

Understanding the role of Proteasome activator complex subunit 4 could open doors to potential therapeutic strategies.